ROCK2抑制剂贝鲁舒地尔全身治疗眼部慢性移植物抗宿主病
这项回顾性病例系列分析了78例接受贝鲁舒地尔200mg/日治疗的类固醇难治性慢性GVHD患者,其中28例完成基线及6个月眼部评估。6个月时53.6%患者oGVHD严重度评分改善,64.8%报告OSDI症状改善,CFS、TBUT、Schirmer试验等客观体征显著改善,视觉 acuity稳定,42.9%患者实现皮质激素减量,治疗耐受性良好。
要点
- 贝鲁舒地尔200mg/日与类固醇难治性oGVHD眼表参数和症状改善相关。
- 6个月时53.6%患者oGVHD严重度评分改善,64.8%OSDI症状改善。
- 43.6%达到全身总体缓解者眼部获益更明显,66.7%oGVHD评分改善。
核心结论
- 全身贝鲁舒地尔与类固醇难治性oGVHD的眼表参数和症状改善相关,耐受性良好。
- 眼部改善与全身缓解密切相关,需前瞻性验证。
研究设计与样本
- 回顾性病例系列,分析78例接受贝鲁舒地尔200mg/日治疗的SR-cGVHD患者,其中40例有oGVHD,28例完成基线和6个月评估。
- 基线中位NIH眼评分2,oGVHD严重度评分9,50.0%有严重全身cGVHD,82.1%有结膜纤维化。
主要发现
- 6个月时53.6%患者oGVHD严重度评分改善,64.8%报告OSDI症状改善。
- 中位CFS从4降至3,TBUT从1.00秒增至2.00秒,Schirmer试验从1.0mm改善至2.0mm。
- 43.6%达到全身总体缓解的患者中,66.7%oGVHD严重度评分改善,80.0%OSDI报告改善。
- 视力保持稳定,42.9%患者实现皮质激素剂量减少。
关键数值与推荐
- 眼部评估包括国际慢性眼部GVHD共识组严重度评分、NIH眼评分(0-3)、CFS(0-4)、TBUT、Schirmer I试验和OSDI。
- 治疗反应率按NIH共识标准评估。
临床怎么用
- 对于类固醇难治性cGVHD伴眼部受累患者,贝鲁舒地尔200mg/日可能改善眼表客观体征和症状。
- 眼部改善与全身缓解相关,全身治疗应答者眼部获益更明显。
局限性
- 回顾性设计,样本量有限,仅28例完成基线和6个月评估。
- 需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy of oral belumosudil on ocular surface disease in patients with steroid-refractory chronic graft-versus-host disease (SR-cGVHD). DESIGN: Retrospective case series. METHODS: In this retrospective study, we analyzed patients with SR-cGVHD and ocular involvement (oGVHD) treated with belumosudil (200 mg daily). Ocular assessments at baseline and 6 months included the International Chronic Ocular GVHD Consensus Group severity score, NIH eye score (0-3), corneal fluorescein staining (CFS, 0-4), tear break-up time (TBUT), Schirmer's I test, and the Ocular Surface Disease Index (OSDI). Treatment response rates were assessed per NIH consensus criteria. RESULTS: Among 78 treated patients, 40 had oGVHD; 28 completed both assessments. The cohort (median baseline NIH eye score: 2; oGVHD severity score: 9) had high-risk cGVHD features: 50.0% had severe systemic cGVHD and 82.1% had conjunctival fibrosis. At 6 months, 53.6% of patients showed improvement in the oGVHD severity score and 64.8% reported symptomatic improvement (OSDI). Objective signs significantly improved: median CFS decreased from 4 to 3, TBUT increased from 1.00 to 2.00 seconds, and Schirmer's test improved from 1.0 to 2.0 mm. A greater ocular benefit was observed in 43.6% of patients who achieved systemic overall response, with 66.7% showing improved oGVHD severity scores and 80.0% reporting better OSDI. Visual acuity remained stable, and 42.9% of patients achieved corticosteroid dose reduction. Treatment was well-tolerated. CONCLUSIONS: Systemic belumosudil was associated with improvements in ocular surface parameters and symptoms in steroid-refractory oGVHD, with favorable tolerability. Ocular improvement was closely linked to systemic response, warranting prospective validation.
引用
- Wu Y, Ye B, Lai X, et al. Systemic Treatment With the ROCK2 Inhibitor Belumosudil in Ocular Chronic Graft-Versus-Host Disease. Am J Ophthalmol. 2026. PMID: 42521137. doi:10.1016/j.ajo.2026.07.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。